Plasmodium immunotherapy

BIOLOGICAL2 trials

Sponsors

CAS Lamvac Biotech Co., Ltd., CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.

Conditions

Advanced Malignant Solid TumorAdvanced Ovarian Cancer

Phase 1

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

RecruitingNCT04165590

CAS Lamvac Biotech Co., Ltd.Advanced Malignant Solid Tumor

Start: 2019-10-24End: 2026-10-31Target: 60Updated: 2024-02-20

Phase 2

Plasmodium Immunotherapy for Advanced Ovarian Cancer

Not yet recruitingNCT05924776

CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.Advanced Ovarian Cancer

Start: 2024-07-20End: 2029-03-30Target: 30Updated: 2024-07-22